Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (CC): Updated analysis of stage II disease from the AVANT phase III randomized trial by the GERCOR group

被引：0

作者：

De Gramont, A. ^{[1
]}

Henriques, J. ^{[2
]}

Baruch, B. ^{[3
,4
]}

Kim, T. W. ^{[5
]}

Martinez-Villacampa, M. ^{[6
]}

Gallego-Plazas, J. ^{[7
]}

Cervantes, A. ^{[8
]}

Shim, K. ^{[9
]}

Jonker, D. J. ^{[10
]}

Guerin-Meyer, V. ^{[11
]}

Mineur, L. ^{[12
]}

Banzi, M. ^{[13
]}

Dewdney, A. ^{[14
]}

Dejthevaporn, T. Sirisingha ^{[15
]}

Bloemendal, H. J. ^{[16
]}

Roth, A. D. ^{[17
]}

Thompson, P. ^{[18
]}

Moehler, M. ^{[19
]}

Aranda Aguilar, E. ^{[20
]}

Andre, T. ^{[21
]}

机构：

[1] Inst Hosp Franco Britannique, Dept Med Oncol, Levallois Perret, France

[2] Univ Hosp Besancon, INSERM, UMR 1098, Methodol & Qual Life Unit Oncol, Besancon, France

[3] Rabin Med Ctr, Davidoff Canc Ctr, Dept Oncol, Petah Tiqwa, Israel

[4] Sackler Sch Med, Tel Aviv, Israel

[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[6] Inst Catala Oncol IDIBELL Hospitalet, Dept Med Oncol, Barcelona, Spain

[7] Gen Univ Elche Hosp, Dept Med Oncol, Elche, Spain

[8] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain

[9] Lakeridge Hlth RS McLaughlin Durham Reg Canc Ctr, Med Oncol, Oshawa, ON, Canada

[10] Univ Ottawa, Ottawa Hosp Res Inst, Div Med Oncol, Dept Med, Ottawa, ON, Canada

[11] Inst Cancerol Ouest Paul Papin, Dept Gastroenterol & Hepatol, Angers, France

[12] Inst St Catherine, Radiotherapy & Oncol GI & Liver, Avignon, France

[13] Azienda Osped Arcispedale Santa Maria Nuova IRCCS, Oncol Unit, Reggio Emilia, Italy

[14] Weston Pk Hosp, Canc Res Ctr, Dept Oncol, Sheffield, S Yorkshire, England

[15] Ramathibodi Hosp, Med Oncol, Bangkok, Thailand

[16] Meander Med Ctr, Dept Internal Med Med Oncol, Amersfoort, Netherlands

[17] HUG, Dept Oncol, Digest Tumour Unit, Geneva, Switzerland

[18] Auckland City Hosp, Dept Med Oncol, Auckland, New Zealand

[19] Univ Med Mainz, Dept Med Oncol, Mainz, Germany

[20] Univ Hosp Reina Sofia, Dept Med Oncol, Cordoba, Spain

[21] Hop St Antoine, Dept Med Oncol, Paris, France

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

553P

引用

页数：1

共 50 条

[11] Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy
Gallois, Claire
Taieb, Julien
Le Corre, Delphine
Le Malicot, Karine
Tabernero, Josep
Mulot, Claire
Seitz, Jean-Francois
Aparicio, Thomas
Folprecht, Gunnar
Lepage, Come
Mini, Enrico
Van Laethem, Jean-Luc
Emile, Jean-Francois
Laurent-Puig, Pierre
CLINICAL CANCER RESEARCH, 2018, 24 (19) : 4745 - 4753
[12] phase II study of oxaliplatin-based regimen in relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: INSPIRE study
Kotaka, M.
Ishibashi, K.
Satake, H.
Tsuji, Y.
Kataoka, M.
Nakamura, M.
Nagata, N.
Sakamoto, J.
Oba, K.
Mishima, H.
ANNALS OF ONCOLOGY, 2020, 31 : S101 - S101
[13] Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
Keiichiro Ishibashi
Toru Aoyama
Masahito Kotaka
Hironaga Satake
Yasushi Tsuji
Masato Kataoka
Masato Nakamura
Naoki Nagata
Junichi Sakamoto
Koji Oba
Hideyuki Mishima
Cancer Chemotherapy and Pharmacology, 2021, 87 : 665 - 672
[14] Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
Ishibashi, Keiichiro
Aoyama, Toru
Kotaka, Masahito
Satake, Hironaga
Tsuji, Yasushi
Kataoka, Masato
Nakamura, Masato
Nagata, Naoki
Sakamoto, Junichi
Oba, Koji
Mishima, Hideyuki
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (05) : 665 - 672
[15] Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration
Yoshino, T.
Yamanaka, T.
Kotaka, M.
Manaka, D.
Eto, T.
Hasegawa, J.
Takagane, A.
Nakamura, M.
Kato, T.
Munemoto, Y.
Nakamura, F.
Bando, H.
Taniguchi, H.
Gamoh, M.
Shiozawa, M.
Sakamoto, J.
Saji, S.
Mizushima, T.
Ohtsu, A.
Mori, M.
ANNALS OF ONCOLOGY, 2017, 28
[16] Considerations regarding an updated meta-analysis of the optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer
Pang, Huayang
Yan, Menghua
Chen, Lihui
Zhao, Zhou
Li, Wei
Zhang, Shouru
Sun, Hao
INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (07) : 4431 - 4432
[17] Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials
Gallois, Claire
Shi, Qian
Pederson, Levi D.
Andre, Thierry
Iveson, Timothy J.
Sobrero, Alberto F.
Alberts, Steven
de Gramont, Aimery
Meyerhardt, Jeffrey A.
George, Thomas
Schmoll, Hans-Joachim E.
Souglakos, Ioannis
Harkin, Andrea
Labianca, Roberto
Sinicrope, Frank A.
Oki, Eiji
Shields, Anthony F.
Boukovinas, Ioannis
Kerr, Rachel
Lonardi, Sara
Yothers, Greg
Yoshino, Takayuki
Goldberg, Richard M.
Taieb, Julien
Papamichael, Demetris
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (19) : 2295 - 2305
[18] Exploratory randomized phase II trial for optimizing treatment dosage and duration of adjuvant S-1 plus oxaliplatin in patients with stage III colon cancer (SOAP trial)
Suwa, Y.
Watanabe, J.
Suwa, H.
Ozawa, M.
Momiyama, M.
Ishibe, A.
Sugano, N.
Yamagishi, S.
Ota, M.
Sekido, H.
Saigusa, Y.
Endo, I.
ANNALS OF ONCOLOGY, 2021, 32 : S161 - S162
[19] S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)
Yoshida, M.
Ishiguro, M.
Ikejiri, K.
Mochizuki, I.
Nakamoto, Y.
Kinugasa, Y.
Takagane, A.
Endo, T.
Shinozaki, H.
Takii, Y.
Mochizuki, H.
Kotake, K.
Kameoka, S.
Takahashi, K.
Watanabe, T.
Watanabe, M.
Boku, N.
Tomita, N.
Nakatani, E.
Sugihara, K.
ANNALS OF ONCOLOGY, 2014, 25 (09) : 1743 - 1749
[20] Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer: a meta-analysis
Kuang, Ziyu
Wang, Jiaxi
Liu, Kexin
Wu, Jingyuan
Li, Jie
INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (05) : 3030 - 3038

← 1 2 3 4 5 →